Loading organizations...
Repairogen develops anti-aging skincare products utilizing proprietary DNA-repair technologies. The company commercializes research focused on enhancing the skin’s natural repair processes after environmental damage, such as UV exposure. Its scientific platform improves intrinsic cellular mechanisms for healing skin and hair DNA, creating advanced formulations that promote healthier skin and counteract aging signs.
Co-founded by Frank Borchetta, Michael Boice, and Frederico Lourenco, Repairogen originated from foundational research at an Ivy League medical institution. Michael Boice, Chief Scientific Officer, brought extensive scientific expertise with a PhD. Their insight identified the opportunity to translate sophisticated cellular DNA repair understanding into accessible consumer products, establishing the company’s mission.
Repairogen serves the broad skincare market, offering consumers products designed to improve skin health and mitigate environmental damage. The company aims to be a leader in DNA-based skin repair solutions, addressing cellular health beyond surface treatments. Its vision involves utilizing biotechnology to establish new standards for effective, science-driven skincare, fostering long-term dermal vitality.
Repairogen has raised $460K across 1 funding round.
Repairogen has raised $460K in total across 1 funding round.
Repairogen has raised $460K across 1 funding round. Most recently, it raised $460K Seed in January 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2014 | $460K Seed | — | Gotham GAL Ventures, Gotham Ventures, Innovation Endeavors, NED Ventures, Rapoport Investments, Howard Lindzon, Techstars, Scott Becker | Announced |
Repairogen has raised $460K in total across 1 funding round.
Repairogen's investors include Gotham Gal Ventures, Gotham Ventures, Innovation Endeavors, NED Ventures, Rapoport Investments, Howard Lindzon, Techstars, Scott Becker.
# Repairogen: High-Level Overview
Repairogen is a biotechnology company developing anti-aging skincare products powered by proprietary DNA-repair technologies.[1][2] The company creates scientifically-proven skincare ingredients and products that target skin aging by reducing DNA damage in skin cells, particularly damage caused by UV exposure.[6] Repairogen serves consumers seeking advanced, science-backed skincare solutions that address cellular-level skin damage rather than surface-level concerns.
The company has raised $1.5 million in total funding[3] and is headquartered in New York.[5] By combining molecular biology with cosmetics, Repairogen positions itself at the intersection of biotechnology and the skincare industry, offering a differentiated approach to anti-aging that leverages cutting-edge DNA repair science.
# Origin Story
Repairogen was co-founded by Michael Boice, who serves as chief scientific officer.[7] The company's founding was rooted in rigorous scientific research, with Boice developing patented technology centered on CUL4A Ubiquitin Ligase—a molecular mechanism for repairing DNA damage.[7] The startup gained early validation by joining the McGovern Center incubator at Cornell University, signaling recognition from academic institutions for the scientific merit of its approach.[7] This academic foundation underscores how the company emerged from deep scientific expertise rather than market-driven product design.
# Core Differentiators
# Role in the Broader Tech Landscape
Repairogen operates within the convergence of biotechnology and consumer beauty—a trend gaining momentum as consumers increasingly demand science-backed, efficacy-driven skincare. The timing is favorable: the global anti-aging skincare market is expanding, and consumers are becoming more sophisticated about ingredient science and cellular mechanisms. By translating cutting-edge molecular biology into consumer products, Repairogen exemplifies how deep-tech innovation can penetrate traditionally marketing-driven industries.
The company also reflects a broader shift toward preventative and cellular-level wellness, where addressing root causes (DNA damage) rather than symptoms (wrinkles) appeals to health-conscious consumers. This positions Repairogen within the larger biotech-to-consumer trend that includes personalized medicine, nutrigenomics, and precision skincare.
# Quick Take & Future Outlook
Repairogen's future likely hinges on clinical validation and market education. While the science is compelling, consumer adoption requires clear communication of how DNA-repair technology translates to visible results. The company's next phase will probably involve expanded clinical trials, strategic partnerships with dermatologists or beauty retailers, and scaling production to meet demand.
The skincare industry's increasing embrace of biotech innovation suggests tailwinds for companies like Repairogen. However, competition from larger beauty conglomerates investing in biotech R&D could intensify. Success will depend on whether Repairogen can maintain its scientific differentiation while building brand recognition in a market dominated by established players. If the company can prove that DNA-repair skincare delivers measurable, superior results, it could establish a new category within premium anti-aging—one defined by molecular science rather than marketing alone.
